SK pharmteco Invests $260 Million to Expand Global Small Molecule and Peptide Production
29 Septiembre 2024 - 6:30PM
Business Wire
- Expansion includes a new 5-story, 136k sq.
ft. multipurpose building in Sejong
- More than 300 new employees to be hired for
the anticipated 2026 opening
SK pharmteco, a global contract development and manufacturing
organization (CDMO), today announced a major expansion of its small
molecule and peptide production capabilities with a $260 million
investment to construct a new state-of-the-art facility in Sejong,
South Korea.
Scheduled to begin operations in late 2026, the new facility
will be the fifth plant the company opens in South Korea and will
be a cornerstone of SK pharmteco's global manufacturing network.
Spanning 135,800 square feet, it will feature eight production
trains with an output of tens of metric tons annually. This
investment also includes state-of-the-art peptide R&D
facilities, cGMP kilo labs, and cGMP pilot plant for peptide
manufacturing. These resources can support early-stage clinical and
commercial production with great flexibility.
Last, the investment also includes building the shell for a
sixth manufacturing plant, which will allow us to quickly expand
capacity in the future.
“This expansion is a testament to our unwavering dedication to
serving the evolving needs of the life sciences industry," said
Joerg Ahlgrimm, CEO of SK pharmteco. "By investing in this new
facility, we're increasing our capacity in Asia in line with our
global expansion strategy and solidifying our position as a trusted
partner for companies developing groundbreaking treatments,
demonstrating our adaptability and reliability in a rapidly
changing industry."
SK pharmteco plans to hire over 300 new employees at the Sejong
site to support this expansion. This investment underscores SK
pharmteco’s commitment to meeting the growing demand for
high-quality peptides and small molecules, essential components of
many innovative therapies, demonstrating our reliability and
dedication to the industry.
The life science industry is experiencing rapid growth, driven
by technological advancements and a rising demand for innovative
treatments. However, the global supply chain for these therapies
faces challenges, including limited manufacturing capacity and
complex regulatory requirements. SK pharmteco's new facility
addresses these challenges by providing a scalable and reliable
solution for producing these critical therapies.
"Our new facility represents a significant investment in our
future and a commitment to delivering exceptional value to our
customers," said Yongwoo Park, SK pharmteco’s President, Small
Molecule, Asia. "By expanding our capacity and capabilities, we can
offer even faster turnaround times, increased flexibility, and a
higher level of quality. This investment further solidifies SK
pharmteco's position as a trusted partner for companies developing
innovative cell and gene therapies and small molecules, enabling us
to accelerate the development and commercialization of
life-changing treatments."
About SK pharmteco
SK pharmteco is a global contract development and manufacturing
organization (CDMO) with production sites, research &
development facilities, and analytical laboratories across the
U.S., Europe, and Korea. The company partners with
biopharmaceutical companies of all sizes to manufacture Active
Pharmaceutical Ingredients (API) and intermediates, cell and gene
therapy technologies, registered starting materials, and analytical
services for the biopharmaceutical industry worldwide. SK pharmteco
is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic
investment company for SK Group, South Korea’s second-largest
conglomerate.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240929693295/en/
Keith Bowermaster, APR, CCMP Communications Consultant
keith.bowermaster@skpt.com
Website: www.skpharmteco.com